Boehringer and Vitae Pharma drug fails in mid-stage trial
July 1, 2015Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes
A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …
FDA sued over failure to disclose Sovaldi data
June 30, 2015Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi
Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …
Celgene enters 10-year $1 billion pact with Juno
June 30, 2015Research and Development, Sales and Marketing CAR-T, Celgene, Chimeric Antigen Receptor Technology, Juno, T Cell Receptor, TCR, brett wells
Celgene has invested $1 billion into Juno Therapeutics as part of a 10-year partnership aiming to study cures for cancer …
BMS’ Opdivo accepted to UK early access scheme
June 30, 2015Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo
Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …
The Partners hires creative director from InVentive
June 30, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Novo Nordisk, The International Aids Society, The partners, inventive, peter henshaw
Brand consultancy The Partners has appointed creative director Peter Henshaw to lead its creative offerings for the agency’s health team. …
Lilly and Immunocore collaborate on melanoma
June 29, 2015Research and Development, Sales and Marketing LY2157299, LY2801653, brett wells, immunocore, lilly
Eli Lilly is teaming up again with UK biotech Immunocore in order to work together on immunotherapy-based clinical trials. Specifically …
UK pharma’s ‘Golden Triangle’ faces competition from new challengers
June 29, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BioGateway, Cambridge, London, Oxford
The UK’s medical and scientific base is regarded as one of the world’s best.
Boehringer scores trial success for Pradaxa antidote
June 29, 2015Research and Development, Sales and Marketing Boehringer, Pradaxa, idarucizumab
Bosses at Boehringer Ingelheim say the latest results of a study of idarucizumab, and antidote for its blockbuster blood-thinner Pradaxa, …
Novartis spends $200m on pain firm Spinifex
June 29, 2015Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex
Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals. …
Bayer’s Eylea approved in Japan
June 29, 2015Sales and Marketing Eylea, Japan, aflibercept. bayer
German firm Bayer has been shown the green light by the Japanese Ministry of Health, Labour and Welfare to market …
Synexus announces new board
June 29, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Synexus, woler
Following a management buyout Synexus has confirmed who its new board members are to steer the UK recruitment and clinical …
EMA waves through a raft of drug recommendations
June 26, 2015Research and Development, Sales and Marketing AbbVie, Alexion, CHMP, EMA, Novartis, Novo Nordisk, brett wells
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended several treatments for marketing …
Valeant looking to buy Zoetis
June 26, 2015Sales and Marketing Actavis, Allergan, Valeant, Zoetis, brett wells
Canadian drugmaker Valeant Pharmaceuticals has made a move to acquire animal health company Zoetis. This is according to the Wall …
UK Court weighs in on Lilly-Actavis Alimta case
June 26, 2015Medical Communications, Sales and Marketing Actavis, Alimta, UK, lilly
Actavis will be infringing Lilly’s patent if it were to produce generic versions of Alimta, the UK Court of Appeal …
Hanover names branding and comms lead
June 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hanover, frances beves
London-based healthcare communications agency Hanover has recruited Frances Beves as a director to join in August. Beves joins as a …
Red Door Unlimited hires new director
June 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kimberly Santiago, Paradigm Communications, Porter Novelli, red door unlimited
Red Door Unlimited has appointed a new director in Kimberly Santiago who joins from Porter Novelli’s sister agency Paradigm Communications. …
Lilly and Novartis face legal challenges
June 25, 2015Medical Communications, Sales and Marketing Gleevec, Glivec, Novartis, cymbalta, imatinib, lilly, zyprexa
Judges in California have ruled that Lilly should face claims it failed to fully disclose the extent of post-withdrawal side …
Senior heads depart AstraZeneca and Takeda
June 25, 2015Medical Communications, Sales and Marketing AstraZeneca, Briggs Morrison, François-Xavier Roger, James Ward-Lilley, Takeda, brett wells
AstraZeneca vice president James Ward-Lilley and Takeda’s chief financial officer François-Xavier Roger are both exiting their respective companies and moving …
Sophia Genetics appoints chief financial officer
June 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Marylin Mermod Schule, Sophia Genetics
Swiss-based Sophia Genetics that deals in data driven medicine has appointed Marylin Mermod Schule to be its chief financial officer. …
China rejects Gilead’s Sovaldi patent
June 24, 2015Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi
Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
